OKLAHOMA CITY, May 11, 2011 /PRNewswire/ -- Graymark Healthcare, Inc. (NASDAQ: GRMH), the nation's second largest
The sale comprised a total of eight stand alone sleep centers, seven located in western New York and one in Florida. Given that the company only performed diagnostic sleep tests at these locations, the sale of this asset is expected to have no effect on Graymark's recurring revenue re-supply business.
"The divestiture of Nocturna East provides us two key benefits," said Stanton Nelson, CEO of Graymark Healthcare. "Primarily, we exited locations that were limited to sleep diagnostics only, whereas we see the real opportunity in our comprehensive care model, including the set up and re-supply of CPAP equipment. As demonstrated by our seven hospital contracts signed to date in 2011, we're developing a platform that oversees the entire lifecycle of the patientfrom referral through continuing care. Secondarily, the proceeds of the divestiture will more than cover our short-term debt obligations and allow management to concentrate on developing our core business."
"It's important to note that Nocturna East represented the only part of our business with this particular limitation," added Nelson. "So we do not foresee any further divesting of our other existing standalone sleep centers."
Graymark operates a total of 98 sleep laboratories nationwide, comprised of 24 standalone or IDTF facilities in large communities and 74 hospital, provider or rural outreach sites. While the care environments may vary based on community need, Graymark ensures that the quality and comprehensiveness of the services provided remain consistently at the highest standard.
About Graymark Healthcare
Headquartered in Oklahoma City, Okla., Graymark Healthcare, Inc. (NASDAQ: GRMH) is the nation's second largest provider of sleep management solutions. In addition to diagnosing and treating over 80 sleep disorders, the company specializes in comprehensive care for Obstructive Sleep Apnea (OSA). Graymark offers its services through 98 sleep laboratories throughout the United States, including standalone or IDTF facilities, rural outreach sites and hospital or provider agreements. For more information, visit www.graymarkhealthcare.com.
Important Cautions Regarding Forward-Looking Statements
This press release may contain forward-looking statements that are based on the company's current expectations, forecasts and assumptions. Forward-looking statements involve risks and uncertainties that could cause actual outcomes and results to differ materially from the company's expectations, forecasts and assumptions. These risks and uncertainties include risks and uncertainties not in the control of the company, including, without limitation, the current economic climate and other risks and uncertainties, including those enumerated and described in the company's filings with the Securities and Exchange Commission, which filings are available on the SEC's website at www.sec.gov. Unless otherwise required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Graymark Healthcare, Inc.
Subscribe to our Free Newsletters!
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All